Loading
A phase 3 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Radiomedix, Inc., completed.
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE is a phase 3 interventional study registered as NCT03673943 by Radiomedix, Inc., with 63 participants recorded, started 2018-08-23 and reaching its primary completion in 2019-03-23. Interventions recorded: 64Cu-DOTATATE. Conditions recorded: Neuroendocrine Tumors.
Linked to the technology Somatostatin receptor PET because the registry names it ("64cu dotatate") among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/